Biotin-thiamine-responsive basal ganglia disease

Last updated
Biotin-thiamine-responsive basal ganglia disease (BTBGD)
Other namesBTRBGD, [1] Biotin-responsive basal ganglia disease (BBGD), [2] Thiamine metabolism dysfunction syndrome 2 (biotin or thiamine-responsive type) (THMD2), [3] Thiamine-responsive encephalopathy, Thiamine transporter-2 deficiency [4]
Specialty Neurometabolic disorders, neurology, internal medicine
Symptoms Subacute encephalopathy; dystonia; spasticity; seizures; dysphagia; ataxia; dysarthria; etc. [5]
Usual onsetChildhood (ages 3-10) [4]
DurationLifelong
CausesFamily history (inherited) [2]
Risk factors Febrile illness; stress; trauma [5]
Diagnostic method Based on symptoms, family history, brain imaging, genetic testing [5]
Management|management= Prevention of symptoms, avoiding stressors, and routine surveillance [5]
Medication Administering biotin and thiamine; symptomatic treatments [5]

Biotin-thiamine-responsive basal ganglia disease (BTBGD) is a rare disease that affects the nervous system, particularly the basal ganglia in the brain. [4] It is a treatable neurometabolic disorder with autosomal recessive inheritance. [2] [1] First described in 1998 [6] and then genetically distinguished in 2005, [7] the disease is characterized by progressive brain damage that, if left untreated, can lead to coma and/or death. [1] Commonly observed in individuals with BTBGD is recurring subacute encephalopathy along with confusion, seizures, and disordered movement (hypokinesia). [8]

Contents

BTBGD has several alternate names, including:

Signs and Symptoms

The onset of signs and symptoms can occur at any age but is most common in childhood between the ages of 3 and 10. [4] Less commonly, it may present in early infancy or adulthood. The neurological symptoms usually present as episodes of increasing severity. A less common exhibition of BTBGD involves persistent symptoms, rather than recurrent episodes. [4] In these cases, fewer symptoms are usually present, with their severity slowly increasing over time.[ citation needed ]

Classic Presentation (Childhood)

Recurrent subacute encephalopathy is the most commonly observed symptom, followed by dystonia, both of which are nearly always present. Additional observed symptoms include spasticity or cogwheel rigidity, seizures, difficulty swallowing (dysphagia), ataxia, slurred speech (dysarthria), ophthalmoplegia, opisthotonus, facial palsy, confusion, hyperreflexia, Babinski responses, and ankle clonus. [5]

Early Infancy Presentation

In early infancy, the presentation of BTBGD is considered as Leigh-like syndrome or atypical infantile spasms. [5] It is characterized by acute encephalopathy, vomiting, metabolic acidosis (specifically lactic acidosis), and poor feeding during the first 3 months of life. [1] [5]

Late-Onset Presentation (Adulthood)

Presentation of late-onset BTBGD is considered a Wernicke-like encephalopathy. [1] [5] It is characterized by ataxia, ophthalmoplegia, double vision (diplopia), rapid and uncontrollable eye movement (nystagmus), status seizures, and droopy eyelid (ptosis). The onset of signs and symptoms for adulthood presentation occurs during or after the second decade of life.[ citation needed ]

Causes

Genetics

SLC19A3 gene mutations cause BTBGD. [4] SLC19A3 is a gene on chromosome 2q36.3 that encodes the protein thiamine transporter 2. [4] [5] Thiamine transporter 2 moves thiamine (vitamin B1) into cells, which is essential for nervous system functioning. Mutations of the gene encoding this protein (SLC19A3) are likely to impair the functioning of this protein and inhibit the transportation and absorption of thiamine.[ citation needed ]

The role of biotin in BTBGD is unclear. [4]

Triggers

Episodes of symptoms can be triggered by several things: [5]

Diagnosis

BTBGD can be diagnosed based on brain imaging and confirmed with genetic testing. [9] Additional diagnostic tools include laboratory testing of biological fluids and reviewing autosomal recessive inheritance in the family history.[ citation needed ]

Clinical Findings

Brain Magnetic Resonance Imaging (MRI)

The MRI of individuals with BTBGD may reveal lesions on the basal ganglia and central bilateral necrosis in the caudate nucleus and putamen. [7] [10] Vasogenic edema is also characteristic of BTBGD. [5] Additional MRI findings include high T2 signal intensity with possible swelling in basal ganglia, and abnormal diffuse involvement of the subcortical white matter, cortical, and infratentorial brain. [5] [11] Involvement in the thalami, brain stem, and cerebellum may also be observed. [11]

Molecular Genetic Testing

Molecular genetic tests that can be performed for BTBGD include: [5]

  • Sequence analysis of the entire coding region or select exons
  • Duplication/deletion analysis
  • Targeted variant analysis

Differential Diagnosis

Other disorders that present similar clinical findings include: [5]

Screening

Family members of individuals with BTBGD may be tested regardless of symptoms. [12] Family members may be affected by the disease, may be asymptomatic carriers of the mutation, or may be completely unaffected. [5] Genetic testing of family members allows for the identification of subtle symptoms, asymptomatic carriers, and increased-risk individuals, which allows for early treatment as needed.[ citation needed ]

Treatment

Treatment of BTBGD is done to manage specific symptoms and concerns. [5] If left untreated, the disease can be fatal. Treatment may vary by symptom, though it is common to administer thiamine (up to 40 mg/kg/day) and sometimes biotin (5-10 mg/kg/day) orally. This treatment is specifically used to address neurological symptoms and can reverse these symptoms if taken early enough. Biotin and thiamine oral therapy must continue throughout the entirety of the individual's life. [5] Other symptomatic treatments include anti-seizure medication to treat seizures and trihexyphenidyl or L-dopa to treat dystonia. Rehab and therapy are used for developmental and social concerns.[ citation needed ]

Management

Management of BTBGD includes prevention of symptoms and routine surveillance. [5] Avoiding stressors is essential in managing BTBGD since stress and trauma can trigger episodes. Fevers are also triggers, so fever control is important. Other triggers that should be avoided include infections and excessive exercise. Routine surveillance should include evaluation of the individual's nervous system, education and development, and any other relevant areas.[ citation needed ]

Epidemiology

The prevalence of BTBGD is unknown. [4] Of the reported cases, it is predominately observed in individuals from Arab populations.

Related Research Articles

<span class="mw-page-title-main">Fragile X syndrome</span> X-linked dominant genetic disorder

Fragile X syndrome (FXS) is a genetic neurodevelopmental disorder characterized by mild-to-moderate intellectual disability. The average IQ in males with FXS is under 55, while about two thirds of affected females are intellectually disabled. Physical features may include a long and narrow face, large ears, flexible fingers, and large testicles. About a third of those affected have features of autism such as problems with social interactions and delayed speech. Hyperactivity is common, and seizures occur in about 10%. Males are usually more affected than females.

Encephalopathy means any disorder or disease of the brain, especially chronic degenerative conditions. In modern usage, encephalopathy does not refer to a single disease, but rather to a syndrome of overall brain dysfunction; this syndrome has many possible organic and inorganic causes.

<span class="mw-page-title-main">Wernicke encephalopathy</span> Medical condition

Wernicke encephalopathy (WE), also Wernicke's encephalopathy, or wet brain is the presence of neurological symptoms caused by biochemical lesions of the central nervous system after exhaustion of B-vitamin reserves, in particular thiamine (vitamin B1). The condition is part of a larger group of thiamine deficiency disorders that includes beriberi, in all its forms, and alcoholic Korsakoff syndrome. When it occurs simultaneously with alcoholic Korsakoff syndrome it is known as Wernicke–Korsakoff syndrome.

<span class="mw-page-title-main">Leigh syndrome</span> Metabolic disease

Leigh syndrome is an inherited neurometabolic disorder that affects the central nervous system. It is named after Archibald Denis Leigh, a British neuropsychiatrist who first described the condition in 1951. Normal levels of thiamine, thiamine monophosphate, and thiamine diphosphate are commonly found, but there is a reduced or absent level of thiamine triphosphate. This is thought to be caused by a blockage in the enzyme thiamine-diphosphate kinase, and therefore treatment in some patients would be to take thiamine triphosphate daily. While the majority of patients typically exhibit symptoms between the ages of 3 and 12 months, instances of adult onset have also been documented.

<span class="mw-page-title-main">Primary familial brain calcification</span> Indiana genetic disorder involving calcification of the basal ganglia

Primary familial brain calcification (PFBC), also known as familial idiopathic basal ganglia calcification (FIBGC) and Fahr's disease, is a rare, genetically dominant or recessive, inherited neurological disorder characterized by abnormal deposits of calcium in areas of the brain that control movement. Through the use of CT scans, calcifications are seen primarily in the basal ganglia and in other areas such as the cerebral cortex.

<span class="mw-page-title-main">Isovaleric acidemia</span> Medical condition disrupting normal metabolism

Isovaleric acidemia is a rare autosomal recessive metabolic disorder which disrupts or prevents normal metabolism of the branched-chain amino acid leucine. It is a classical type of organic acidemia.

<span class="mw-page-title-main">Maple syrup urine disease</span> Autosomal recessive metabolic disorder

Maple syrup urine disease (MSUD) is a rare, inherited metabolic disorder that affects the body’s ability to metabolize amino acids due to a deficiency in the activity of the branched-chain alpha-ketoacid dehydrogenase (BCKAD) complex. It particularly affects the metabolism of amino acids- leucine, isoleucine, and valine. With MSUD, the body is not able to properly break down these amino acids, therefore leading to the amino acids to build up in urine and become toxic. The condition gets its name from the distinctive sweet odor of affected infants' urine and earwax due to the buildup of these amino acids.

Pantothenate kinase-associated neurodegeneration (PKAN), formerly called Hallervorden–Spatz syndrome, is a genetic degenerative disease of the brain that can lead to parkinsonism, dystonia, dementia, and ultimately death. Neurodegeneration in PKAN is accompanied by an excess of iron that progressively builds up in the brain.

<span class="mw-page-title-main">MELAS syndrome</span> Mitochondrial disease

MELAS is one of the family of mitochondrial diseases, which also include MIDD, MERRF syndrome, and Leber's hereditary optic neuropathy. It was first characterized under this name in 1984. A feature of these diseases is that they are caused by defects in the mitochondrial genome which is inherited purely from the female parent. The most common MELAS mutation is mitochondrial mutation, mtDNA, referred to as m.3243A>G.

<span class="mw-page-title-main">Thiamine deficiency</span> Human disease

Thiamine deficiency is a medical condition of low levels of thiamine (vitamin B1). A severe and chronic form is known as beriberi. The name beriberi was possibly borrowed in the 18th century from the Sinhalese phrase බැරි බැරි (bæri bæri, “I cannot, I cannot”), owing to the weakness caused by the condition. The two main types in adults are wet beriberi and dry beriberi. Wet beriberi affects the cardiovascular system, resulting in a fast heart rate, shortness of breath, and leg swelling. Dry beriberi affects the nervous system, resulting in numbness of the hands and feet, confusion, trouble moving the legs, and pain. A form with loss of appetite and constipation may also occur. Another type, acute beriberi, found mostly in babies, presents with loss of appetite, vomiting, lactic acidosis, changes in heart rate, and enlargement of the heart.

Dravet syndrome (DS), previously known as severe myoclonic epilepsy of infancy (SMEI), is an autosomal dominant genetic disorder which causes a catastrophic form of epilepsy, with prolonged seizures that are often triggered by hot temperatures or fever. It is very difficult to treat with anticonvulsant medications. It often begins before one year of age, with six months being the age that seizures, char­ac­ter­ized by prolonged convulsions and triggered by fever, usually begin.

<span class="mw-page-title-main">GLUT1 deficiency</span> Medical condition


GLUT1 deficiency syndrome, also known as GLUT1-DS, De Vivo disease or Glucose transporter type 1 deficiency syndrome, is an autosomal dominant genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier. Glucose Transporter Type 1 Deficiency Syndrome has an estimated birth incidence of 1 in 90,000 to 1 in 24,300. This birth incidence translates to an estimated prevalence of 3,000 to 7,000 in the U.S.

<span class="mw-page-title-main">Thiamine transporter 2</span> Protein-coding gene in the species Homo sapiens

Thiamine transporter 2 (ThTr-2), also known as solute carrier family 19 member 3, is a protein that in humans is encoded by the SLC19A3 gene. SLC19A3 is a thiamine transporter.

Progressive Myoclonic Epilepsies (PME) are a rare group of inherited neurodegenerative diseases characterized by myoclonus, resistance to treatment, and neurological deterioration. The cause of PME depends largely on the type of PME. Most PMEs are caused by autosomal dominant or recessive and mitochondrial mutations. The location of the mutation also affects the inheritance and treatment of PME. Diagnosing PME is difficult due to their genetic heterogeneity and the lack of a genetic mutation identified in some patients. The prognosis depends largely on the worsening symptoms and failure to respond to treatment. There is no current cure for PME and treatment focuses on managing myoclonus and seizures through antiepileptic medication (AED).

<span class="mw-page-title-main">Paroxysmal exercise-induced dystonia</span> Medical condition

Paroxysmal exercise-induced dystonia (PED) is a rare neurological disorder that belongs to the paroxysmal dyskinesias, a group of rare movement disorders that involve attacks of hyperkinesia with intact consciousness. It is characterized by sudden, transient, involuntary movements, often including repetitive twisting motions and painful posturing triggered by exercise or other physical exertion. The term paroxysmal indicates that the episodes are sudden and short lived and usually unpredicted, and return to normal is rapid. The number of reported cases of people with PED is very small leading to difficulty in studying and classifying this disease and most studies are limited to a very small number of test subjects.

<span class="mw-page-title-main">Basal ganglia disease</span> Group of physical problems resulting from basal ganglia dysfunction

Basal ganglia disease is a group of physical problems that occur when the group of nuclei in the brain known as the basal ganglia fail to properly suppress unwanted movements or to properly prime upper motor neuron circuits to initiate motor function. Research indicates that increased output of the basal ganglia inhibits thalamocortical projection neurons. Proper activation or deactivation of these neurons is an integral component for proper movement. If something causes too much basal ganglia output, then the ventral anterior (VA) and ventral lateral (VL) thalamocortical projection neurons become too inhibited, and one cannot initiate voluntary movement. These disorders are known as hypokinetic disorders. However, a disorder leading to abnormally low output of the basal ganglia leads to reduced inhibition, and thus excitation, of the thalamocortical projection neurons which synapse onto the cortex. This situation leads to an inability to suppress unwanted movements. These disorders are known as hyperkinetic disorders.

<span class="mw-page-title-main">Neuroferritinopathy</span> Medical condition

Neuroferritinopathy is a genetic neurodegenerative disorder characterized by the accumulation of iron in the basal ganglia, cerebellum, and motor cortex of the human brain. Symptoms, which are extrapyramidal in nature, progress slowly and generally do not become apparent until adulthood. These symptoms include chorea, dystonia, and cognitive deficits which worsen with age.

<span class="mw-page-title-main">Kufor–Rakeb syndrome</span> Medical condition

Kufor–Rakeb syndrome (KRS) is an autosomal recessive disorder of juvenile onset also known as Parkinson disease-9 (PARK9). It is named after Kufr Rakeb in Irbid, Jordan. Kufor–Rakeb syndrome was first identified in this region in Jordan with a Jordanian couple's 5 children who had rigidity, mask-like face, and bradykinesia. The disease was first described in 1994 by Najim Al-Din et al. The OMIM number is 606693.

<span class="mw-page-title-main">Kohlschütter–Tönz syndrome</span> Medical condition

Kohlschütter–Tönz syndrome (KTS), also called amelo-cerebro-hypohidrotic syndrome, is a rare inherited syndrome characterized by epilepsy, psychomotor delay or regression, intellectual disability, and yellow teeth caused by amelogenesis imperfecta. It is a type A ectodermal dysplasia.

<span class="mw-page-title-main">Aicardi–Goutières syndrome</span> Medical condition

Aicardi–Goutières syndrome (AGS), which is completely distinct from the similarly named Aicardi syndrome, is a rare, usually early onset childhood, inflammatory disorder most typically affecting the brain and the skin. The majority of affected individuals experience significant intellectual and physical problems, although this is not always the case. The clinical features of AGS can mimic those of in utero acquired infection, and some characteristics of the condition also overlap with the autoimmune disease systemic lupus erythematosus (SLE). Following an original description of eight cases in 1984, the condition was first referred to as 'Aicardi–Goutières syndrome' (AGS) in 1992, and the first international meeting on AGS was held in Pavia, Italy, in 2001.

References

  1. 1 2 3 4 5 6 Al-Anezi A, Sotirova-Koulli V, Shalaby O, Ibrahim A, Abdulmotagalli N, Youssef R, Hossam El-Din M (April 2022). "Biotin-thiamine responsive basal ganglia disease in the era of COVID-19 outbreak diagnosis not to be missed: A case report". Brain & Development. 44 (4): 303–307. doi:10.1016/j.braindev.2021.12.003. PMC   8696467 . PMID   34953623.
  2. 1 2 3 4 "Biotin-thiamine-responsive basal ganglia disease - About the Disease - Genetic and Rare Diseases Information Center". rarediseases.info.nih.gov. Retrieved 2022-11-27.
  3. 1 2 3 "#607483 - THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2". omim.org. Retrieved 2022-11-27.
  4. 1 2 3 4 5 6 7 8 9 10 "Biotin-thiamine-responsive basal ganglia disease: MedlinePlus Genetics". medlineplus.gov. Retrieved 2022-11-27.
  5. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Tabarki, Brahim; Al-Hashem, Amal; Alfadhel, Majid (1993), Adam, Margaret P.; Mirzaa, Ghayda M.; Pagon, Roberta A. (eds.), "Biotin-Thiamine-Responsive Basal Ganglia Disease", GeneReviews, University of Washington, Seattle, PMID   24260777 , retrieved 2022-11-27
  6. ↑ Ozand PT, Gascon GG, Al Essa M, Joshi S, Al Jishi E, Bakheet S, et al. (July 1998). "Biotin-responsive basal ganglia disease: a novel entity". Brain. 121 ( Pt 7) (7): 1267–1279. doi: 10.1093/brain/121.7.1267 . PMID   9679779.
  7. 1 2 Zeng WQ, Al-Yamani E, Acierno JS, Slaugenhaupt S, Gillis T, MacDonald ME, et al. (July 2005). "Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3". American Journal of Human Genetics. 77 (1): 16–26. doi:10.1086/431216. PMC   1226189 . PMID   15871139.
  8. ↑ "Biotin thiamine responsive basal ganglia disease". Orphanet. Retrieved 2022-11-27.
  9. ↑ Majumdar S, Salamon N (March 2022). "Biotin-thiamine-responsive basal ganglia disease: A case report". Radiology Case Reports. 17 (3): 753–758. doi:10.1016/j.radcr.2021.12.029. PMC   8717433 . PMID   35003475.
  10. ↑ Alfadhel M, Umair M, Almuzzaini B, Alsaif S, AlMohaimeed SA, Almashary MA, et al. (October 2019). "Targeted SLC19A3 gene sequencing of 3000 Saudi newborn: a pilot study toward newborn screening". Annals of Clinical and Translational Neurology. 6 (10): 2097–2103. doi:10.1002/acn3.50898. PMC   6801173 . PMID   31557427.
  11. 1 2 Alfadhel M, Almuntashri M, Jadah RH, Bashiri FA, Al Rifai MT, Al Shalaan H, et al. (June 2013). "Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases". Orphanet Journal of Rare Diseases. 8 (1): 83. doi: 10.1186/1750-1172-8-83 . PMC   3691666 . PMID   23742248.
  12. ↑ Aljabri MF, Kamal NM, Arif M, AlQaedi AM, Santali EY (October 2016). "A case report of biotin-thiamine-responsive basal ganglia disease in a Saudi child: Is extended genetic family study recommended?". Medicine. 95 (40): e4819. doi:10.1097/MD.0000000000004819. PMC   5059037 . PMID   27749535.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.